SNGX
HEALTHCARESoligenix Inc.
AI Insight
What's Moving SNGX Today?
No stock-specific AI insight has been generated for SNGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.28$6.23
$0.38
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-1.42
Dividend Yield—
Dividend / Share—
ROE-326.9%
Profit Margin—
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding14.8M
SNGX News
23 articles- Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola VaccineYahoo Finance·Jun 8, 2026
- Soligenix, Inc. Files SEC Form 8-K for May 28, 2026 – Company Information and Legal ExhibitsMinichart·May 29, 2026
- SNGX Stock More Than Doubles In Pre-Market, Eyes $1 Breakout For First Time In A Month – Ebola Vaccine Optimism Fuels Retail FrenzyStocktwits·May 27, 2026
- Soligenix (SNGX) Stock Soars 72% On ThermoVax Platform Promise Amid Ebola Outbreak Caused By Bundibugyo VirusBenzinga·May 27, 2026
- Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in CongoYahoo Finance·May 26, 2026
- SNGX: Continuing to Analyze FLASH2 DataYahoo Finance·May 14, 2026
- Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsYahoo Finance·May 8, 2026
- SNGX: FLASH2 Trial Recommended to Stop for FutilityYahoo Finance·Apr 29, 2026
- SNGX Phase 3 Trial Halted on HyBryteAdvfn·Apr 28, 2026
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaYahoo Finance·Apr 28, 2026
- Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachYahoo Finance·Apr 21, 2026
- Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusYahoo Finance·Apr 20, 2026
- Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsYahoo Finance·Apr 17, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Apr 10, 2026
- SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26Yahoo Finance·Apr 6, 2026
- Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and TherapyYahoo Finance·Apr 2, 2026
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and TherapyBenzinga·Apr 2, 2026
- Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 ResultsYahoo Finance·Apr 1, 2026
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial ResultsBenzinga·Mar 31, 2026
- Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet DiseaseYahoo Finance·Mar 26, 2026
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's DiseaseBenzinga·Mar 26, 2026
- Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones ApproachYahoo Finance·Mar 25, 2026
All 23 articles loaded
Price Data
Open$0.39
Previous Close$0.39
Day High$0.41
Day Low$0.38
52 Week High$6.23
52 Week Low$0.28
52-Week Range
$0.28$6.23
$0.38
Fundamentals
Market Cap$6M
P/E Ratio—
EPS$-1.42
Dividend Yield—
Dividend / Share—
ROE-326.9%
Profit Margin—
Debt / Equity—
Trading
Volume742K
Avg Volume (10D)—
Shares Outstanding14.8M
About Soligenix Inc.
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—